| [1] |
黄烽．强直性脊柱炎[M]．北京：人民卫生出版社，2011.
|
| [2] |
Proft F,Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria[J]. Ther Adv Musculoskelet Dis, 2018, 10(5/6): 129-139.
|
| [3] |
Linden SD,Valkenburg HA,Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis[J]. Arthritis Rheum, 1984, 27(3): 357-359.
|
| [4] |
Sieper J,Rudwaleit M,Baraliakos X, et al. The assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis[J]. Ann Rheum Dis, 2009, 68(Suppl 2): ii1-i44.
|
| [5] |
Smolen JS,Schöls M,Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force[J]. Ann Rheum Dis, 2018, 77(1): 3-17.
|
| [6] |
National Institute for Health and Care Excellence (UK). Spondyloarthritis in Over 16s: Diagnosis and Management //NICE Guideline, No. 65 [M/OL]. London: National Institute for Health and Care Excellence (UK)，2017.
|
| [7] |
Van Der Heijde D,Ramiro S,Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis[J]. Ann Rheum Dis, 2017, 76(6): 978-991.
|
| [8] |
Ward MM,Deodhar A,Akl EA, et al. American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis[J]. Arthritis Care Res (Hoboken), 2016, 68(2): 151-166.
|
| [9] |
Sieper J,Deodhar A,Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study[J]. Ann Rheum Dis, 2017, 76(3): 571-592.
|
| [10] |
Baraliakos X,Kiltz U,Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis[J]. Rheumatology (Oxford), 2017, 56(1): 95-102.
|
| [11] |
Molto A,Granger B,Wendling D, et al. Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort[J]. Joint Bone Spine, 2017, 84(1): 79-82.
|
| [12] |
Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N,Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials[J]. Lancet, 2013, 382(9894): 769-779.
|
| [13] |
Haibel H,Rudwaleit M,Braun J, et al. Six months open label trial of leflunomide in active ankylosing spondylitis[J]. Ann Rheum Dis, 2005, 64(1): 124-126.
|
| [14] |
Braun J,Zochling J,Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial[J]. Ann Rheum Dis, 2006, 65(9): 1147-1153.
|
| [15] |
Haibel H,Brandt HC,Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial[J]. Ann Rheum Dis, 2007, 66(3): 419-421.
|
| [16] |
Lukas C,Landewé R,Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis[J]. Ann Rheum Dis, 2009, 68(1): 18-24.
|
| [17] |
Calin A,Garrett S,Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index[J]. J Rheumatol, 1994, 21(12): 2281-2285.
|
| [18] |
Wei JC,Tsai WC,Citera G, et al. Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis[J]. Int J Rheum Dis, 2018, 21(7): 1443-1451.
|
| [19] |
Maksymowych WP,Wichuk S,Dougados M, et al. Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis[J]. Ann Rheum Dis, 2018, 77(1): 78-84.
|
| [20] |
Sieper J,Lenaerts J,Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1[J]. Ann Rheum Dis, 2014, 73(1): 101-107.
|
| [21] |
Flint J,Panchal S,Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids[J]. Rheumatology (Oxford), 2016, 55(9): 1693-1697.
|
| [22] |
Calligaro A,Hoxha A,Ruffatti A, et al. Are biological drugs safe in pregnancy？[J]. Reumatismo, 2015, 66(4): 304-317.
|
| [23] |
Ai JW,Zhang S,Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies[J]. J Rheumatol, 2015, 42(12): 2229-2237.
|
| [24] |
薛勤，汪年松．解读肿瘤坏死因子拮抗剂应用中结核病的预防与管理专家共识[J]．世界临床药物，2016，17(8)：505-507.
|
| [25] |
Ozguler Y,Hatemi G,Ugurlu S, et al. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy[J]. Rheumatol Int, 2016, 36(12): 1719-1725.
|
| [26] |
Kim YJ,Kim YG,Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors[J]. Rheumatology (Oxford), 2014, 53(8): 1477-1481.
|
| [27] |
汤善宏，曾维政，蒋明德.2014年美国胃肠病学会指南：免疫抑制剂治疗过程中HBV再激活的预防及治疗[J]．临床肝胆病杂志，2015，31(4): 483-489.
|
| [28] |
Corbett M,Soares M,Jhuti G, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation[J]. Health Technol Assess, 2016, 20(9): 1-334, v-vi.
|
| [29] |
Dougados M,Van Der Heijde D,Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol (Hoboken, N．J.), 2014, 66(8): 2091-2102.
|
| [30] |
Hamilton L,Barkham N,Bhalla A, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics[J]. Rheumatology (Oxford), 2017, 56(2): 313-316.
|
| [31] |
Simmons ED,Distefano RJ，Zheng Y, et al. Thirty-six years experience of cervical extension osteotomy in ankylosingspondylitis: techniques and outcomes[J/OL]. Spine (Phila Pa 1976), 2006, 31(26)：3006-12. doi： 10.1097/01.brs.0000250663.12224.d9. |
| [32] |
Tokala DP,Lam KS,Freeman BJ, et al. C7 decancellisation closing wedge osteotomy for the correction of fixed cervico-thoracic kyphosis[J]. Eur Spine J, 2007, 16(9): 1471-1478.
|
| [33] |
Willems KF,Slot GH,Anderson PG, et al. Spinal osteotomy in patients with ankylosing spondylitis: complications during first postoperative year[J]. Spine (Phila Pa 1976), 2005, 30(1): 101-107.
|
| [34] |
Chen IH,Chien JT,Yu TC. Transpedicular wedge osteotomy for correction of thoracolumbar kyphosis in ankylosing spondylitis: experience with 78 patients[J]. Spine (Phila Pa 1976), 2001, 26(16): E354-E360.
|
| [35] |
Van Royen BJ,De Kleuver M,Slot GH. Polysegmental lumbar posterior wedge osteotomies for correction of kyphosis in ankylosing spondylitis[J]. Eur Spine J, 1998, 7(2): 104-110.
|
| [36] |
Langeloo DD,Journee HL,Pavlov PW, et al. Cervical osteotomy in ankylosing spondylitis: evaluation of new developments[J]. Eur Spine J, 2006, 15(4): 493-500.
|
| [37] |
Mackay K,Mack C,Brophy S, et al. The Bath ankylosing spondylitis radiology index (BASRI): a new, validated approach to disease assessment[J]. Arthritis Rheum, 1998, 41(12): 2263-2270.
|
| [38] |
沈彬，裴福兴，邱贵兴．强直性脊柱炎的诊断与治疗骨科专家共识[J]．中华骨科杂志，2012，32(9)：895-898.
|
| [39] |
Goodman SM,Springer B,Guyatt G, et al. 2017 American college of rheumatology/American association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty[J]. Arthritis Rheumatol，2017，69(8)：1538-1551.
|